SFJ and Apellis Pharmaceuticals (Nasdaq: APPL) are collaborating on the development of APL-2, a novel therapeutic targeting complement, in hematologic indications including Paroxysmal Nocturnal Hemoglobinuria (PNH).
Location | Pleasanton, California |
CEO | Robert DeBenedetto |
Partner | Kurt von Emster |
Website | www.sfj-pharma.com |